Purdue Sold Plant to Novo Nordisk

| By | Novo Nordisk, Purdue Pharma
0
141

Purdue has sold its Treyburn, North Carolina, plant to Novo Nordisk for an undisclosed sum, according to an announcement Purdue CEO Craig Landau sent to the plant’s employees.

In support of our business strategy and ongoing efforts to strengthen and diversify the Purdue business, we have completed a thorough analysis of our manufacturing operations and capabilities, As a result of this evaluation, we have been working with Novo Nordisk, and together identified a potential transaction that will meet the needs of both companies. While financial details are not being publicly disclosed at this time, Novo Nordisk has purchased our Treyburn plant,

Landau said in the statement.

The Treyburn plant was constructed to provide redundancy and a backup facility for the company’s Wilson location.

Given the market dynamics and expected demand for our current portfolio of marketed products, the continued operation of Treyburn can no longer be justified. Further, a thorough analysis of Purdue’s current and future business requirements shows that with additional staffing and the continued leadership of personnel already in place, our Wilson facility is in a position to meet today’s product requirements as well as enable the growth strategy for Purdue and all of its subsidiaries going forwardб

Landau said.

Following the close, Purdue will lease back the Treyburn space from Novo Nordisk, occupy it through the fall, and plan to vacate the facility as of Dec. 1, 2019.